ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Leukemia & Lymphoma

LLS Precision Medicine Trial May Change Treatment Paradigm for AML Patients

The Leukemia & Lymphoma Society will head up the Beat AML Master Trial, which will use a precision medicine protocol under the support and guidance from the FDA. Image © Minerva Studio/Shutterstock.com 

Leukemia & Lymphoma

Kinase oncoproteins and growth factors both activate the proto-oncogene c-FOS and DUSP1, allowing the persistence of residual leukemia cell populations despite tyrosine kinase inhibitor therapy.

Patients with mucosa-associated lymphoid tissue (MALT) lymphoma had improved event-free survival when treated with chlorambucil plus rituximab compared with either therapy alone.

Unmutated immunoglobulin heavy chain variable region gene (IGHV) status does not adversely impact survival among ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

We spoke with Dr. Anas Younes about the molecular characteristics of diffuse large B-cell lymphoma.

The emergence of ibrutinib-resistant chronic lymphocytic leukemia (CLL) can be detected prior to clinical relapse, according to an analysis of patients from four ibrutinib trials.

Despite significant toxicities, idelalisib improved time to progression for patients with treatment-resistant chronic lymphocytic leukemia.

Combined miniCHOP and treatment with the fully-human anti-CD20 monoclonal antibody ofatumumab is associated with improved overall survival among elderly patients diagnosed with diffuse large B-cell lymphoma.

Pages

Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.